Boehringer Ingelheim To Buy ViraTherapeutics In Deal For Cancer-Killing Viruses.

Forbes (9/13, Weintraub) reports Boehringer Ingelheim announced that it plans to acquire Austria-based ViraTherapeutics for €210 million ($244 million), “becoming the third major company this year to bag technology based around cancer-killing viruses.” F...